Tag Archives: Aratana Therapeutics

Analysts’ Perspective: Sierra Wireless (SWIR), Aratana Therapeutics (PETX), Farmers National (FMNB)

Investment Analysts at ROTH Capital upgraded Sierra Wireless Inc. (NASDAQ:SWIR) shares from Neutral to Buy rating.

Sierra Wireless, Inc. engages in the development of device-to-cloud products and services for the Internet of Things.

*

Brokerage Firm Stifel upgraded Aratana Therapeutics Inc. (NASDAQ:PETX) shares from Hold to Buy rating with a price target of $8.

Aratana Therapeutics, Inc. is a development stage biopharmaceutical company, which focuses on the licensing, development and commercialization of innovative prescription medications for pets, or pet therapeutics.

*

Farmers National Banc Corp. (NASDAQ:FMNB) shares were upgraded by analysts at Raymond James from Market Perform to Outperform rating.

Farmers National Banc Corp. operates as a bank holding company, which owns and supervises its subsidiaries’ banking operations.

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/

Analysts’ View: Carlyle Group (CG), Aratana Therapeutics (PETX), Otonomy (OTIC)

Brokerage Firm Citigroup upgraded Carlyle Group L.P. (NASDAQ:CG) shares from Neutral to Buy rating.

The Carlyle Group LP engages in a multi-product global alternative asset management.

*

Investment Analysts at CL King upgraded Aratana Therapeutics Inc. (NASDAQ:PETX) shares from Neutral to Buy rating.

Aratana Therapeutics, Inc. is a development stage biopharmaceutical company, which focuses on the licensing, development and commercialization of innovative prescription medications for pets, or pet therapeutics.

*

Otonomy Inc. (NASDAQ:OTIC) shares were upgraded by analysts at Piper Jaffray from Neutral to Overweight of rating.

Otonomy, Inc. engages in the research, development, and manufacture of biopharmaceutical products.

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/